Phillips HA , Favre I , Kirkpatrick M , Zuberi SM , Goudie D , Heron SE , Scheffer IE , Sutherland GR , Berkovic SF , Bertrand D , Mulley JC .

	Figure 1. Scottish family, with family members carrying the mutated CHRNB2 codon287 indicated by “m”
	Figure 2. DNA sequence of CHRNB2, showing the c1025G→A transition. The upper chromatogram shows the mutation. The lower chromatogram shows the control sequence.
	Figure 3. Similarities within the M2 domain. Codon 287, located near the extracellular end of the M2 domain, is indicated by the box.
	Figure 4. A, left panel, Neuronal α4β2 heteropentameric receptor resulting from the assembly of two α4 and three β2 subunits. Right panel, α4β2 is shown as a pentamer with two potential ACh-binding sites. “β2*” identifies the V287M amino acid substitution. The ACh receptor can assemble without any mutated β2 subunit (α4β2 wild-type receptor) or with one, two, or three mutated β2* subunits. B, upper panel, Current traces elicited by consecutive applications of four or five increasing ACh concentrations (horizontal bars). The values above each bar indicate the concentration of ACh applied to the cell. Lower panel, Differences in ACh affinity are emphasized in a log-log plot. The logarithm of the absolute value of the current (measured in the upper panel, Log [−I]) is plotted as a function of the logarithm of ACh concentrations (Log [ACh]). −I and [ACh] are expressed in nA and nM, respectively. Values are mean ± SEM, with n=9 (α4β2), n=17 (α4β2*), and n=10 (α4[β2*+β2]). Solid lines are the best linear regression throughout data points. C, upper panel, Representative macroscopic currents recorded in oocytes expressing either the wild-type or mutated β2 subunit. Currents evoked by four ACh concentrations (0.1, 0.2, 0.8 and 8 μM) are superimposed. Cells were held at −100 mV and challenged with ACh (10 s) once every 120 s. Bars indicate ACh applications. Lower panel, ACh activation curves for α4β2, α4β2* and α4(β2*+β2). Dose-response curves were normalized to the maximal current amplitude of each cell. Values are mean ± SEM. For each ACh concentration, 3–8 independent measurements were averaged. Values of the curve fits are given in the text.

Anand, Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. 1991, Pubmed, Xenbase

Anand, Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. 1991, Pubmed , Xenbase
Bertrand, Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy. 1998, Pubmed , Xenbase
Cooper, Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. 1991, Pubmed
Covernton, Multiple components in the agonist concentration-response relationships of neuronal nicotinic acetylcholine receptors. 2000, Pubmed , Xenbase
De Fusco, The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. 2000, Pubmed
Devillers-Thiéry, Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels. 1993, Pubmed
Hirose, A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy. 1999, Pubmed
Kuryatov, Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors. 1997, Pubmed , Xenbase
Monteggia, Cloning and transient expression of genes encoding the human alpha 4 and beta 2 neuronal nicotinic acetylcholine receptor (nAChR) subunits. 1995, Pubmed
Nelson, A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. 1989, Pubmed
Oldani, Autosomal dominant nocturnal frontal lobe epilepsy. A video-polysomnographic and genetic appraisal of 40 patients and delineation of the epileptic syndrome. 1998, Pubmed
Phillips, A de novo mutation in sporadic nocturnal frontal lobe epilepsy. 2000, Pubmed
Phillips, Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. 1998, Pubmed
Rempel, The structures of the human neuronal nicotinic acetylcholine receptor beta2- and alpha3-subunit genes (CHRNB2 and CHRNA3). 1998, Pubmed
Sáenz, Autosomal dominant nocturnal frontal lobe epilepsy in a Spanish family with a Ser252Phe mutation in the CHRNA4 gene. 1999, Pubmed
Scheffer, Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. 1995, Pubmed
Steinlein, An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. 1997, Pubmed
Steinlein, A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. 1995, Pubmed
Steinlein, Independent occurrence of the CHRNA4 Ser248Phe mutation in a Norwegian family with nocturnal frontal lobe epilepsy. 2000, Pubmed
Weiland, An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. 1996, Pubmed , Xenbase
Willoughby, Molecular cloning of a human neuronal nicotinic acetylcholine receptor beta 3-like subunit. 1993, Pubmed